TICKERNERD
Menu
CRISCRISHealthcare · Biotechnology

CRIS Stock Forecast: Curis, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$1.00

The 4 Wall Street analysts covering Curis, Inc. hold a median 12-month price target of $43 — +4200.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.4M
Ticker Nerd rank
36 / 100
Median analyst target
$43
Analysts covering
4
Revenue$0.0−100.0% y/y
Operating income−$9.9M
Net income−$8.6M
Free cash flow−$9.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

CRIS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Curis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Growth
67
Issuance
61
Accruals
57
Revisions
46
Quality
40
Momentum
15
Volatility
14
Value
5

Size (99): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRIS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRIS, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $20Median $43High $65

The green dot is the last close — the median target sits +4200.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026HC Wainwright & Co.ReiteratesBuy$43
24 July 2026HC Wainwright & Co.MaintainsBuy$17 → $43
24 July 2026HC Wainwright & Co.MaintainsBuy—
20 Mar 2026HC Wainwright & Co.ReiteratesBuy—
20 Mar 2026HC Wainwright & Co.ReiteratesBuy$17
19 May 2025HC Wainwright & Co.AssumesBuy$17
31 Mar 2025HC Wainwright & Co.MaintainsBuy—
10 Dec 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
1 Nov 2024HC Wainwright & Co.MaintainsBuy—
27 Sept 2024HC Wainwright & Co.ReiteratesBuy$26
1 Aug 2024HC Wainwright & Co.ReiteratesBuy—
15 May 2024Cantor FitzgeraldReiteratesOverweight—
15 May 2024HC Wainwright & Co.ReiteratesBuy—
15 May 2024Truist SecuritiesMaintainsBuy—
8 May 2024HC Wainwright & Co.ReiteratesBuy—
9 Feb 2024HC Wainwright & Co.MaintainsBuy—
17 Nov 2023Truist SecuritiesInitiatesBuy—
29 Sept 2023HC Wainwright & Co.ReiteratesBuy$6.00 → $51
25 Sept 2023HC Wainwright & Co.ReiteratesBuy$6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRIS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CRIS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Curis, Inc. (CRIS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.3×

Cheaper than 72% of US stocks

Price / sales
0.6×

Cheaper than 80% of US stocks

Price / book
0.4×

Cheaper than 86% of US stocks

EV / EBITDA
0.1×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−833.4%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−138.8%

Higher than 10% of US stocks

Return on assets
−93.2%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Curis, Inc. (CRIS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Curis, Inc. has a market value of $2.4M and an enterprise value of −$1.9M.

  • Revenue in the twelve months to 30 June 2026: $4.3M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$21.2M, a −490.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−14.22.

  • Free cash flow in the twelve months to 30 June 2026: −$30.6M.

  • Shares outstanding: 1.9M.

  • Trailing P/E: 0.3×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Curis, Inc. employs 20 people — $216K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

CRIS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRISCuris, Inc.$2.4M
36
OGENOragenics, Inc.$2.1M
10
PPCBPropanc Biopharma, Inc.$2.1M
40
ARTLArtelo Biosciences, Inc.$2.2M
15
VBIOValion Bio, Inc.$1.9M
2
MTNBMatinas BioPharma Holdings, Inc.$2.4M
44
CDTCDT Equity, Inc.$2.4M
11

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Curis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRIS news & analysis

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

PRNewsWire · 13 Aug 2026negative

Curis, Inc. announced the pricing of its $5.6 million public offering, in which new and existing healthcare-focused institutional investors will purchase roughly 3.73 million shares (or pre-funded warrants) with accompanying warrants at a combined offering price of $1.50 per share and warrant. The proceeds relate to funding the company's development of its IRAK4 and FLT3 inhibitor emavusertib.

Why it matters — CRIS watchers would care because this capital raise provides funding for the company's pipeline but issues additional shares, diluting existing shareholders.

Curis Doses First Five Patients in TakeAim CLL Study

PRNewsWire · 30 July 2026positive

Curis announced it has dosed the first five patients in its TakeAim CLL study, which evaluates emavusertib (CA-4948), an orally available IRAK4 and FLT3 inhibitor, in patients with Chronic Lymphocytic Leukemia.

Why it matters — This enrollment milestone moves the TakeAim CLL study forward and marks progress in Curis's clinical development of emavusertib for CLL patients.

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Benzinga · 24 July 2026positive

Curis Inc. announced updated positive clinical trial results for its investigational drug emavusertib and provided expanded trial timeline guidance.

Why it matters — A CRIS watcher would care because the positive clinical data for emavusertib, a blood cancer drug, supports the company's development pipeline and a December readout is now in focus.

FAQ

Frequently asked questions about CRIS stock

What is the CRIS stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Curis, Inc. have a median 12-month price target of $43, with estimates ranging from $20 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRIS stock a buy right now?

Of the 4 analysts covering Curis, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Curis, Inc. 36 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRIS?

As at 19 Sept 2026, Curis, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

Will CRIS stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +4200.0% from the last close, and Ticker Nerd's factor model ranks Curis, Inc. 36 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRIS stock forecast for 2030?

No analyst covering Curis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRIS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $65 over the next 12 months.

What does Curis, Inc. do?

Curis Inc. is a biotechnology company focused on developing and commercializing innovative therapeutics for cancer treatment.

What is the latest news on CRIS?

The most recent item we track (PRNewsWire, 13 Aug 2026): "Curis, Inc. Announces Pricing of $5.6 Million Public Offering". Curis, Inc. announced the pricing of its $5.6 million public offering, in which new and existing healthcare-focused institutional investors will purchase roughly 3.73 million shares (or pre-funded warrants) with accompanying warrants at a combined offering price of $1.50 per share and warrant. The proceeds relate to funding the company's development of its IRAK4 and FLT3 inhibitor emavusertib.

Company

About Curis, Inc.

Curis Inc. is a biotechnology company focused on developing and commercializing innovative therapeutics for cancer treatment. The company’s current portfolio centers on targeted drug candidates designed to address specific cancer-driving pathways and patient groups, with programs spanning hematologic malignancies and solid tumors. Its work includes small-molecule and antibody-based therapies, as well as marketed or advanced-stage assets in oncology and related disease areas. Curis also collaborates with research and development partners to advance its pipeline and expand the clinical profile of its programs. Based in Lexington, Massachusetts, Curis Inc. plays a specialized role in the oncology drug development market, where it contributes to the discovery and testing of precision medicines intended for use in areas with significant unmet medical need.

CEO Mr. James E. Dentzer · 20 employees · United States · https://www.curis.com